BioTuesdays

Category - Markets

oncosec
Markets

BTIG starts OncoSec Medical at buy; PT $10

BTIG initiated coverage of OncoSec Medical (NASDAQ:ONCS) with a “buy” rating and $10 price target. The stock closed at $5.23 on March 5. OncoSec is working to develop safe versions of the powerful immune stimulator...

March 8, 2021
TransMedics logo
Markets

Canaccord ups TransMedics PT to $46 from $20

Canaccord Genuity raised its price target for TransMedics (NASDAQ:TMDX) to $46 from $20, predicting 2021 would be transformational with two potential product approvals and a roll-out of an enhanced support model. The...

March 3, 2021
NLS-Pharmaceutics-Logo
Markets

Maxim starts NLS Pharmaceutics at buy; PT $8

Maxim Group launched coverage of NLS Pharmaceutics AG (NASDAQ:NLSP) with a “buy” rating and $8 price target. The stock closed at $2.83 on March 2. NLS is developing Quilience for narcolepsy and Nolazol for ADHD; both...

March 3, 2021
Heat Biologics
Markets

Cantor starts Heat Biologics at OW; PT $22

Cantor Fitzgerald initiated coverage of Heat Biologics (NASDAQ:HTBX) with an “overweight” rating and $22 price target. The stock closed at $7.87 on March 2. Heat Biologics is developing proprietary immunotherapy...

March 3, 2021
Angion-Logo
Markets

Stifel starts Angion Biomedica at buy; PT $40

Stifel launched coverage of Angion Biomedica (NASDAQ:ANGN) with a “buy” rating and $40 price target. The stock closed at $19.92 on March 1. Angion’s lead asset, ANG-3777, is a mimetic of hepatocyte growth factor (HGF)...

March 2, 2021
Pharvaris-Logo
Markets

SVB Leerink starts Pharvaris at OP; PT $50

SVB Leerink initiated coverage of Pharvaris B.V. (NASDAQ:PHVS) with an “outperform” rating and $50 price target. The stock closed at $39.23 on March 1. Pharvaris is developing therapies for rare diseases, with a focus...

March 2, 2021
Avita Medical
Markets

Piper starts Avita Medical at OW; PT $27

Piper Sandler launched coverage of Avita Medical (NASDAQ:RCEL) with an “overweight” rating and $27 price target. The stock closed at $21.49 on March 1. Avita makes Recell, which uses a patient’s own skin to make a cell...

March 2, 2021
Lucira-Health-Logo
Markets

WB starts Lucira Health at OP

William Blair initiated coverage of Lucira Health (NASDAQ:LHDX) with an “outperform” rating, based on “our outlook for a series of positive catalysts on commercialization and manufacturing as well as what we believe is...

March 2, 2021